JNK-9L

• Description:

  JNK-9L (Compound 9l) is a BBB-penetrable and ATP-competitive JNK inhibitor with IC50s of 0.099 and 0.148 μM for JNK1 and JNK3, respectively. JNK-9L significantly inhibits c-jun phosphorylation and Streptozotocin (HY-13753) -induced ROS generation with an IC50 of 0.8 nM. JNK-9L can be used for neurodegenerative disorders like Parkinson’s disease research[1].

• UNSPSC:

  12352005

• Target:

  JNK; Reactive Oxygen Species (ROS)

• Related Pathways:

  Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Purity:

  98.06

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  FC1=CC(C2=NC(NC(C=C3)=CC=C3N4C=NC(N5CCOCC5)=N4)=NC=C2)=CC(N6CCOCC6)=C1

• Molecular Formula:

  C26H27FN8O2

• Molecular Weight:

  502.54

• References & Citations:

  [1]Kamenecka T, et al. Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. J Med Chem. 2010 Jan 14;53 (1) :419-31.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  JNK1; JNK3

• CAS Number:

  [1128096-64-9]